Progesterone therapy in the prevention of pregnancy loss
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20253284Keywords:
Pregnancy loss, Recurrent miscarriages, Progesterone therapyAbstract
Pregnancy loss, including early miscarriage and recurrent pregnancy loss (RPL), is a significant concern in reproductive health. Progesterone, a key steroid hormone, plays a critical role in preparing the endometrium, modulating immune tolerance, and maintaining uterine quiescence. This narrative review explores the current evidence on the mechanisms of progesterone action, its clinical efficacy in preventing pregnancy loss, available routes of administration, international guideline recommendations, and emerging therapeutic strategies. Randomized controlled trials (RCTs) notably the progesterone in spontaneous miscarriage (PRISM) and progesterone in recurrent miscarriage (PROMISE) studies-have demonstrated mixed results, with benefits more apparent in women with a history of RPL and those experiencing early pregnancy bleeding. These findings are supported by recent meta-analyses, which suggest that treatment success may depend on proper patient selection and timing of intervention. Among administration methods, vaginal progesterone remains the preferred route due to its targeted endometrial effects and reduced systemic side effects. However, oral dydrogesterone, a synthetic progestin, has shown potential in improving patient adherence. Recommendations from major clinical guidelines including those from the National Institute for Health and Care Excellence (NICE), the American College of Obstetricians and Gynecologists (ACOG), and the International Federation of Gynecology and Obstetrics (FIGO)-differ slightly based on interpretation of available data and individualized care approaches. Emerging directions include novel synthetic progestins with enhanced receptor specificity, combination regimens incorporating progesterone with surgical or immunologic therapies, and biomarker-guided approaches involving serum progesterone and progesterone-induced blocking factor (PIBF) levels. Advances in genetic and molecular profiling offer further potential for personalized medicine. Further research is warranted to refine patient selection, establish standardized protocols, and ultimately improve pregnancy outcomes
Metrics
References
World Health Organization. Miscarriage: epidemiology and burden. Available at: https://www. who.int/newsroom/factsheets/detail/maternal-mortality. Accessed on 25 July 2025.
Practice Committee of the American Society for Reproductive Medicine: Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012,98:1103-11. DOI: https://doi.org/10.1016/j.fertnstert.2012.06.048
Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587-603. DOI: https://doi.org/10.1016/S0140-6736(15)00837-5
Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33. DOI: https://doi.org/10.1016/S2214-109X(14)70227-X
Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189-94. DOI: https://doi.org/10.1056/NEJM198807283190401
American College of Obstetricians and Gynecologists [ACOG]: Early Pregnancy Loss. ACOG Practice Bulletin No. 200. Obstet Gynecol. 2018;132:197-207. DOI: https://doi.org/10.1097/AOG.0000000000002899
Wang Q, Ma J, Lan Y. Long-term trends in the global burden of maternal abortion and miscarriage from 1990 to 2021: joinpoint regression and age-period-cohort analysis. BMC Public Health. 2025;25:1554. DOI: https://doi.org/10.1186/s12889-025-22716-1
Genovese HG, McQueen DB. The prevalence of sporadic and recurrent pregnancy loss. Fertil Steril. 2023;120:934-6. DOI: https://doi.org/10.1016/j.fertnstert.2023.08.954
Shah NM, Lai PF, Imami N, Johnson MR. Progesterone-related immune modulation of pregnancy and labor. Front Endocrinol. 2019;10:198. DOI: https://doi.org/10.3389/fendo.2019.00198
Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018;8(8):CD005943. DOI: https://doi.org/10.1002/14651858.CD005943.pub5
Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016;20(41):1-92. DOI: https://doi.org/10.3310/hta20410
Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst Rev. 2019;2019(11):CD003511. DOI: https://doi.org/10.1002/14651858.CD003511.pub5
Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. N Engl J Med. 2019;380(19):1815-24. DOI: https://doi.org/10.1056/NEJMoa1813730
Cope DI, Monsivais D. Progesterone Receptor Signaling in the Uterus Is Essential for Pregnancy Success. Cells. 2022;11(9):1474. DOI: https://doi.org/10.3390/cells11091474
Holdsworth-Carson SJ, Menkhorst E, Maybin JA. Cyclic processes in the uterine tubes, endometrium, myometrium, and cervix: pathways and perturbations. Mol Hum Reprod. 2023;29:012. DOI: https://doi.org/10.1093/molehr/gaad012
Tong J, Lv S, Yang J, Li H, Li W, Zhang C. Decidualization and Related Pregnancy Complications. Matern Fetal Med. 2021;4(1):24-35. DOI: https://doi.org/10.1097/FM9.0000000000000135
Da Silva ID, Wuidar V, Zielonka M. Unraveling the Dynamics of Estrogen and Progesterone Signaling in the Endometrium: An Overview. Cells. 2024,13:1236. DOI: https://doi.org/10.3390/cells13151236
Raghupathy R, Szekeres-Bartho J. Progesterone: A Unique Hormone with Immunomodulatory Roles in Pregnancy. Int J Mol Sci. 2022;23(3):1333. DOI: https://doi.org/10.3390/ijms23031333
Szekeres-bartho J. Progesterone induced blocking factor in health and disease. Explorat Immunol. 2021;1:406-17. DOI: https://doi.org/10.37349/ei.2021.00027
Shynlova O, Nadeem L, Zhang J. Reprint of: Myometrial activation: Novel concepts underlying labor. Placenta. 2020;98:29-37. DOI: https://doi.org/10.1016/j.placenta.2020.08.014
Coomarasamy A, Devall AJ, Brosens JJ, Quenby S, Stephenson MD, Sierra S, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167-76. DOI: https://doi.org/10.1016/j.ajog.2019.12.006
Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med. 2015;373(22):2141-8. DOI: https://doi.org/10.1056/NEJMoa1504927
Devall AJ, Papadopoulou A, Podesek M, Haas DM, Price MJ, Coomarasamy A, et al. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021;4(4):CD013792. DOI: https://doi.org/10.1002/14651858.CD013792.pub2
Wang X-X, Luo Q, Bai W-P. Efficacy of progesterone on threatened miscarriage: Difference in drug types. J Obstet Gynaecol Res. 2019;45:794-802. DOI: https://doi.org/10.1111/jog.13909
Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020;24(33):1-70. DOI: https://doi.org/10.3310/hta24330
McLindon LA, James G, Beckmann MM, Bertolone J, Mahomed K, Vane M, et al. Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial. Hum Reprod. 2023;38(4):560-8. DOI: https://doi.org/10.1093/humrep/dead029
Naghshineh E, Tehrani HG, Sharifian F. A Comparison of Oral Dydrogesterone with Vaginal Progesterone for Luteal-Phase Support in In vitro Fertilization: A Randomized Controlled Trial. Adv Biomed Res. 2023;12:132. DOI: https://doi.org/10.4103/abr.abr_253_22
Endo N, Rahayu LP, Yamamura T, Tanaka H, Tanaka T. Intravaginal administration of progesterone using a new technique for sustained drug release in goats. J Reprod Dev. 2020;66(5):489-92. DOI: https://doi.org/10.1262/jrd.2019-151
Wagh GN, Kundavi Shankar KM, Bachani S. A review of conventional and sustained-release formulations of oral natural micronized progesterone in obstetric indications. Drugs Context. 2021;10:2021-7. DOI: https://doi.org/10.7573/dic.2021-7-1
Kriplani A, Kamilya GS, Devi TR, Taneja A, Pawar A, Nagesh GK, et al. Oral dydrogesterone versus oral micronized progesterone in threatened miscarriage: protocol paper for a randomized controlled trial. Reprod Fertil. 2025;6(1):e240044. DOI: https://doi.org/10.1530/RAF-24-0044
Jiang L, Luo Z-Y, Hao G-M. Effects of intramuscular and vaginal progesterone supplementation on frozenthawed embryo transfer. Sci Rep. 2019;9:15264. DOI: https://doi.org/10.1038/s41598-019-51717-5
Karadeniz H, Demirci N, Özkan FS. Progesterone-Related Issues and Coping Strategies for for Women Undergoing Assisted Reproductive Treatment. Gazi Med J. 2023;11(3):300-7. DOI: https://doi.org/10.14235/bas.galenos.2023.72691
Tehraninejad ES, Alizadeh S, Nekoo EA, Zargarzadeh N, Shariat M, Haghollahi F, et al. Comparing the outcomes of in-vitro fertilization in patients receiving vaginal, subcutaneous, and intramuscular progesterone for luteal phase support: a three-armed randomized controlled trial. BMC Womens Health. 2024;24(1):481. DOI: https://doi.org/10.1186/s12905-024-03337-z
Wise J. NICE recommends progesterone to prevent early miscarriage. BMJ. 2021;375:n2896. DOI: https://doi.org/10.1136/bmj.n2896
Duncan WC. Did the NICE guideline for progesterone treatment of threatened miscarriage get it right? Reprod Fertil. 2022;3:4-6. DOI: https://doi.org/10.1530/RAF-21-0122
American College of Obstetricians and Gynecologists [ACOG]. Updated Clinical Guidance for the Use of Progestogen Supplementation for the Prevention of Recurrent Preterm. Birth. 2023.
Shehata H, Elfituri A, Doumouchtsis SK, Zini ME, Ali A, Jan H, et al. FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage. Int J Gynaecol Obstet. 2023;161(1):3-16. DOI: https://doi.org/10.1002/ijgo.14717
Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, et al. Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies. Endocrinology. 2017;158(1):170-82. DOI: https://doi.org/10.1210/en.2016-1426
Islam MS, Afrin S, Jones SI. Selective progesterone receptor modulators—mechanisms and therapeutic utility. Endocr Rev. 2020;41:012. DOI: https://doi.org/10.1210/endrev/bnaa012
Khalid A, Khaliq S, Gill M. Serum Progesterone an Indicator of Viable Pregnancy in First Trimester. Pak J Med Health Sci. 2019;13.
Gong Y, Jiang T, Sun Y, Wu GL, Han BW, Shi Y, et al. Can single progesterone concentration predict miscarriage in early pregnant women with threatened miscarriage: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024;24(1):133. DOI: https://doi.org/10.1186/s12884-024-06303-7
Lim MK, Ku CW, Tan TC, Lee YHJ, Allen JC, Tan NS. Characterisation of serum progesterone and progesterone-induced blocking factor (PIBF) levels across trimesters in healthy pregnant women. Sci Rep. 2020;10(1):3840. DOI: https://doi.org/10.1038/s41598-020-59452-y
Downloads
Published
How to Cite
Issue
Section
